Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Cash from Financing Activities (2019 - 2025)

Historic Cash from Financing Activities for Benitec Biopharma (BNTC) over the last 6 years, with Q2 2025 value amounting to $2.5 million.

  • Benitec Biopharma's Cash from Financing Activities fell 9365.13% to $2.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $70.5 million, marking a year-over-year increase of 361.02%. This contributed to the annual value of $70.5 million for FY2025, which is 361.02% up from last year.
  • Latest data reveals that Benitec Biopharma reported Cash from Financing Activities of $2.5 million as of Q2 2025, which was down 9365.13% from $28.4 million recorded in Q1 2025.
  • Over the past 5 years, Benitec Biopharma's Cash from Financing Activities peaked at $40.1 million during Q2 2024, and registered a low of $3000.0 during Q1 2021.
  • For the 5-year period, Benitec Biopharma's Cash from Financing Activities averaged around $16.7 million, with its median value being $16.9 million (2022).
  • In the last 5 years, Benitec Biopharma's Cash from Financing Activities skyrocketed by 4572051.28% in 2024 and then tumbled by 9365.13% in 2025.
  • Benitec Biopharma's Cash from Financing Activities (Quarter) stood at $12.7 million in 2021, then grew by 26.42% to $16.0 million in 2022, then plummeted by 99.76% to $39000.0 in 2023, then surged by 45720.51% to $17.9 million in 2024, then plummeted by 85.76% to $2.5 million in 2025.
  • Its last three reported values are $2.5 million in Q2 2025, $28.4 million for Q1 2025, and $17.9 million during Q4 2024.